News

BioMed SA eyes new road map to greater economic wins

BioMed SA President Ann Stevens (Photo by Lyndsey Johnson) By W. Scott Bailey, San Antonio Business ...

Military champion has Prytime Medical ready for prime time

Prytime Medical Devices Inc. CEO David Spencer said his company is poised to take its flagship technology ...

Industry Publications

The Mission

The Mission is published by the University of Texas Health Science Center.

UTSA Discovery

UTSA Discovery is published annually for the Office of the Vice President for Research by the Office ...

News
How a San Antonio Company Joined In to Help Conjoined Twins In Need
April 15, 2016

Written by David Holley, Xconomy Texas, on Apr 15, 2016 01:39 pm

San Antonio - [Corrected 4:05 p.m. See below.] For a few hours this week, the country was focused on a pair of infant twins in the South Texas town of Corpus Christi, who were conjoined below the waist. Surgeons at Driscoll Children's Hospital successfully separated the 10-month old babies, Ximena and Scarlett Hernandez-Torres, after 12 hours of surgery on April 12.

Part of the successful operation can be traced to San Antonio. CellRight Technologies, a maker of cadaver-derived bone and tissue grafts, had some of its dermal graft flown to the hospital when surgeons realized they might need more skin to complete the operation.

In the end, some of CellRight's Matrix IQ Dermis product was used on the twins to help repair their (now separate) abdominal walls, says CellRight CEO Jesus Hernandez. The company's product is derived from human skin, which is put through a sterilization process that CellRight calls BioRinse, making it so the recipient's body doesn't reject the tissue, Hernandez says. [Updated to reflect correct spelling of product name and the placement of dermis on the abdominal wall, not skin.]

"The way we decellularize our product, we remove the DNA and the cells, so your body doesn't recognize it," Hernandez says.

Founded in 2012, CellRight first developed a scaffold product for repairing bones. CellRight has a method of processing human bone-which comes from donated cadavers-so that it can be sterilized, without it losing a type of protein that Hernandez says is thought to help in bone grafting: bone morphogenetic proteins.

If CellRight's scaffold, called the Matrix OI, is mixed with a patient's stem cells-done by either soaking the scaffold in a patient's blood or by removing cells from bone marrow-Hernandez says the proteins will stimulate the cells, spurring bone growth.

The company is certainly in a competitive market, with countless tissue and bone grafting technologies swarming the market. That includes Durham, NC-based Bioventus and its FDA-approved scaffold Silhouetteas well as Medtronic's more controversial Infuse Bone Graft. Even something as simple as a ceramic scaffold, or as complicated as a titanium implant like that made by Mequon, WI-based Titan Spinecompetes with CellRight.

CellRight hasn't sought out regulatory approval for its products as 510(k) medical devices, however, fearing the cost and that the high level of disclosure could allow competitors insight into its work, Hernandez says.

Currently, the company is registered as a tissue bank. It has registered its products with the FDA as minimally manipulated productsHernandez says. [Corrected to reflect name of FDA registration process.]

Though that may limit its scalability, Hernandez is hopeful that a larger acquirer will see the potential in the tools. Even though CellRight products are not regulated as 510(k) medical devices, he says each time CellRight creates a batch of products, they are tested by two separate and independent labs to ensure safety and that the stem cells will have an environment to proliferate.

The ability to help in the separation of the conjoined twins (who were actually part of a rare type of triplets) makes doing business worth it, Hernandez says.

"It's why we do what we do," he says.

Stay informed. Subscribe to BioMed SA news alerts.